MetaCap

Psyence Biomedical (PBM) vs Quoin Pharmaceuticals (QNRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Quoin Pharmaceuticals (QNRX) has outperformed Psyence Biomedical (PBM) over the past year, losing 82.1% versus a loss of 94.9%. Psyence Biomedical is the larger company by market cap ($15.8 million vs $15.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PBM-94.90%QNRX-82.07%
+28%-37%-102%
Nov 21, 20251 yearNov 20, 2026
PBM-100.00%QNRX-99.98%
+25%-41%-106%
Dec 6, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PBM versus QNRX key metrics
MetricPBMQNRX
Share price$2.97$3.28
Market cap$15.80M$15.76M
1-day change+3.85%-2.35%
YTD return-89.90%-77.27%
1-year return-94.90%-82.07%
5-year return—-99.99%
P/E ratio (TTM)—7.45
EPS (TTM)$-12.56$0.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$1.01M$-15.80M
52-week high$73.44$23.50
52-week low$1.92$3.18
Distance from 52-week high-95.96%-86.04%
Analyst consensus—none
Avg. price target upside—+565.55%
Average volume61.93K541.26K
Shares outstanding5.32M4.80M
Employees124
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • QNRX has outperformed PBM by 12.8 percentage points over the past year.

About Psyence Biomedical

PBM stock →

Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

About Quoin Pharmaceuticals

QNRX stock →

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

PBM vs QNRX FAQ

Which is bigger, Psyence Biomedical or Quoin Pharmaceuticals?

Psyence Biomedical (PBM) is larger, with a market capitalization of $15.80M compared with $15.76M for Quoin Pharmaceuticals (QNRX).

Which stock has performed better over the past year, PBM or QNRX?

QNRX returned -82.07% over the past 12 months, compared with -94.90% for PBM (price return, excluding dividends). Past performance does not predict future results.

Are Psyence Biomedical and Quoin Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons